Lewes, DE – According to filings with the U.S. Securities and Exchange Commission, Samsara Therapeutics is raising $12,713,496.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jens Eckstein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Samsara Therapeutics
Samsara Therapeutics, Inc. is biopharmaceutical company aiming to discover first-in-class therapeutics that treat rare genetic and neurodegenerative disease, and extend healthy lifespan. Samsaras platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy. Samsara Therapeutics is a global biotech company with operations in Oxford and Boston and significant academic collaborations in Paris and Graz.

To learn more about Samsara Therapeutics, visit http://www.samsaratherapeutics.com/

Contact:
Jens Eckstein, Chief Executive Officer
617-413-8733
https://www.linkedin.com/in/jenseckstein/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved